Oral JAK inhibitor baricitinib effective in JIA

被引：0
|
作者：
Jessica McHugh
机构：
[1] Nature Reviews Rheumatology,
来源：
Nature Reviews Rheumatology | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
引用
收藏
页码：539 / 539
相关论文
共 50 条
  • [1] Oral JAK inhibitor baricitinib effective in JIA
    McHugh, Jessica
    NATURE REVIEWS RHEUMATOLOGY, 2023, 19 (09) : 539 - 539
  • [2] Effective treatment of oral lichen planus with the JAK inhibitor baricitinib
    Moussa, Anthony
    Colla, Themis
    Morrison, Brendan
    Sinclair, Rodney
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (02) : 276 - 277
  • [3] Effective treatment of nail lichen planus with the JAK inhibitor baricitinib
    Chim, Ivana
    Sinclair, Rodney
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 52 - 53
  • [4] The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
    Shi, Jack G.
    Chen, Xuejun
    Lee, Fiona
    Emm, Thomas
    Scherle, Peggy A.
    Lo, Yvonne
    Punwani, Naresh
    Williams, William V.
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1354 - 1361
  • [5] A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
    Taylor, Peter C. C.
    Laedermann, Cedric
    Alten, Rieke
    Feist, Eugen
    Choy, Ernest
    Haladyj, Ewa
    de la Torre, Inmaculada
    Richette, Pascal
    Finckh, Axel
    Tanaka, Yoshiya
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [6] Clinical Response of Dermatomyositis to Therapy with the JAK Inhibitor Baricitinib
    Fischer, Kristina
    Aringer, Martin
    Beissert, Stefan
    Guenther, Claudia
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 4 - 4
  • [7] A phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate to severe psoriasis
    Menter, Alan
    Disch, Damon
    Clemens, Jeffrey
    Janes, Jonathan
    Papp, Kim
    Macias, William
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB162 - AB162
  • [8] Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
    Scheinberg, Morton
    Machado, Luis Antonio
    Castro, Luiz Guilherme M.
    Ferreira, Sineida Berbert
    Michalany, Nilceo
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2021, 4
  • [9] JAK INHIBITOR BARICITINIB MODULATES HUMAN INNATE AND ADAPTIVE IMMUNE SYSTEM
    Kubo, S.
    Nakayamada, S.
    Ma, X.
    Lee, S.
    Yamagata, K.
    Nakano, K.
    Iwata, S.
    Hanami, K.
    Fukuyo, S.
    Miyagawa, I.
    Tamaki, Y.
    Tanaka, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1236 - 1236
  • [10] Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients
    Kim, Hanna
    Brooks, Kristina M.
    Tang, Cheng Cai
    Wakim, Paul
    Blake, Mary
    Brooks, Stephen R.
    Sanchez, Gina A. Montealegre
    de Jesus, Adriana A.
    Huang, Yan
    Tsai, Wanxia Li
    Gadina, Massimo
    Prakash, Apurva
    Janes, Jonathan Marcus
    Zhang, Xin
    Macias, William L.
    Kumar, Parag
    Goldbach-Mansky, Raphaela
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (02) : 364 - 373
12345